Safety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: A dose-escalation phase I study trial

Article

Abstract: Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effectiv

Palabras claves:

Human epidermal growth factor receptor, Immunogenicity, Prostate cancer, safety, Therapeutic vaccine

Autores:

Aira L.E., Bárbara Wilkinson, Caballero I., Casacó Parada A.R., Coba K., González J.G., González N., Lavastida A., Luaces P.L.o., Macías A.E., Mazorra Z., Mesa M., Popa X., Rivero J., Sanchez B., Santiesteban Y., Suárez E., Tania Crombet, Troche M.

Fuentes:

scopus